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Background: We aimed to better discriminate metastasized (lymphogen/occult/both combined) from non-metastasized
seminoma based on post-transcriptional changes examined in the peripheral blood.
Methods: Total RNAs including small RNAs were isolated from the peripheral blood of patients suffering from
metastasized testicular tumours (lymphogen, n = 5, clinical stage IIb/c; occult, n = 5, clinical stage I) and
non-metastasized patients (n = 5, clinical stage I). Small RNA next generation sequencing (SOLID, Life Technologies)
was employed to examine post-transcriptional changes. We searched for small RNAs showing at least 50 reads and a
significant≥ 2-fold difference using peripheral blood small RNAs of non-metastasized tumours as the reference group.
Candidate small RNAs were examined in univariate logistic regression analysis and combinations of two small RNAs
were further examined using support vector machines.
Results: On average 1.3x107, 1.2x107 and 1.2x107 small RNA reads were detectable in non-metastasized, lymphogen and
occult metastasized seminoma, respectively of which 73-76% remained after trimming. From these between
80-82% represented annotated reads and 7.2-7.8% (1.6-1.7x104) were annotated small RNA tags. Of them 137 small RNAs
showed > 50 reads and a≥ two-fold difference to the reference. In univariate analysis we detected 33-35 different small
RNAs which significantly discriminated lymphogen/occult/combined metastasized from non-metastasized seminoma and
among these different comparisons it were the same small RNAs in 44-79%. Many combinations of two of these small
RNAs completely discriminated metastasized from non-metastasized seminoma irrespective of the metastasis subtype.
Conclusions: Metastasized (either lymphogen or occult) seminoma can be completely discriminated from
non-metastasized seminoma with a combination of two small RNAs measured in the peripheral blood.
Keywords: Testis tumour, Gene expression, Small RNA, MicroRNA, Metastasized seminoma, Next generation
sequencing, Risk factor, Tumour marker, BloodBackground
Testicular tumor, as the most common tumor in young
men, is associated with a 5 year survival rate close to
100% in early stages. Pure seminoma are the most fre-
quent histological subtype (55%) nowadays and more than
70% of patients present without visible metastasis at pri-
mary staging [1]. Gold standard for primary staging is
computed tomography (CT) of the chest, abdomen and
pelvis to detect metastases. In truly non-metastasized cli-
nical stage I (cS I) patients are cured by orchidectomy* Correspondence: Dr.ChristianRuf@gmx.de
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unless otherwise stated.alone, but despite modern staging and classification
procedures up to 30% of cS I seminoma patients’ bear
occult metastasis in primary staging and relapse after
orchidectomy alone [2,3]. Until today no reliable bio-
logical parameters exist and clinical parameter are
showing a concordance of 65% only in differentiating
occult metastasized stages from non-metastasized semi-
noma [4]. Identification of occult metastasized patients
is one of the main goals to prevent toxicity (e.g. cardiovas-
cular and kidney disease, secondary malignancies and de-
creased fertility) caused by unnecessary adjuvant treatment
or diagnostic procedures (additional radiation exposure due
to quarterly CT scans) during follow up [5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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certain set of micro RNAs (miRNA) might be suitable for
discriminating between seminoma bearing patients and
healthy persons [6-8]. Expression of miRNAs in testicular
germ cell cancer is also known to be associated with the
histologic subtype [7] as well as cisplatin resistance [9,10].
Additionally miRNAs are known to be involved in differ-
ent processes of metastatic spread in other tumours [11].
Among seminoma bearing patients circulating tumour
cells are already detected in the peripheral blood [12]. We
wondered whether changes in microRNA expression in
the peripheral blood might be able to discriminate metas-
tasized (either lymphogen, occult or a combination of
both subtypes) from non-metastasized seminoma. We uti-
lized an agnostic approach investigating the whole gen-
ome for any kind of small RNA species suitable to
discriminate metastatic stage in seminoma employing next
generation sequencing (NGS) on peripheral blood samples
drawn at the time of the primary tumour’s diagnosis.
Results
Characteristics of seminoma groups
The average age at diagnosis was 39.1 (+/- 7.2) years for
non-metastasized, higher (45.2 years, +/- 10.8) for lym-
phogen metastasized and lower (32.1 years, +/- 5.4) for
occult metastasized seminoma. Primary tumor size was
comparable between lymphogen and occult metasta-
sized seminoma (37.8 mm and 38.6 mm, respectively),
but smaller (23.8 mm) in non-metastasized seminoma
(Table 1).
RNA isolation
Per 2.5 ml whole blood we isolated about the same
amount (mean) of total RNA from seminoma patients
without metastasis (7.7 μg, +/-1.9), lymphogen metastasis
(4.9 μg, +/-2.0 μg) and occult metastasis (6.8 μg, +/-2.4,
Table 1). The RNA integrity number (RIN) ranged be-
tween 7.0-8.6 per group. No DNA contamination could be
detected in our samples.
Analysis of small RNA next generation sequencing results
The average total number of reads for lymphogen/occult
metastasized and non-metastasized seminoma was
1.3x107, 1.2x107 and 1.2x107 and on average 73-76%
remained for further analysis after trimming of the reads
(Table 2). From these reads 80-84% appeared annotated
reads with 7.2-7.8% (1.6-1.7x104) representing annotated
small RNAs. Of them 137 small RNAs showed > 50
reads and a two-fold difference to the reference. In
univariate analysis we identified 33/34 and 35 small
RNA species which significantly discriminated lym-
phogen/occult metastasized and both metastasis sub-
types combined from non-metastasized seminoma,
respectively (Table 3). The overlap of small RNAsseparating either lymphogen or occult metastasis from
non-metastasized seminoma was 47-48% and increased
up to 79% when comparing lymphogen and occult small
RNAs candidates with the small RNAs based on the com-
bined metastasis subtypes (Figure 1). We finally employed
support vector machines which completely separated lym-
phogen, occult metastasis and the combined metastasis
subtypes from non-metastasized seminoma using a com-
bination of two small RNA species only (Table 4).
Altogether, 891, 668 and 87 combinations allowed a
complete separation of lymphogen (n = 5), occult metasta-
sis (n = 5) and the combined metastasis subtypes (n = 10)
from non-metastasized seminoma (n = 5), respectively.
Discussion
In our study we aimed to better discriminate metasta-
sized (either lymphogen or occult subtypes or both com-
bined) from non-metastasized seminoma based on small
RNA changes examined in the peripheral blood. A whole
genome screening on small RNA species was performed
employing NGS. We demonstrated each metastasis sub-
type and its combination to be completely discriminated
from non-metastasized seminoma using two small RNAs
combined.
MicroRNAs are previously described to be involved in
different distant (e.g. migration, angiogenesis and colo-
nization of distant organs) and local (e.g. changes in
tumor microenvironment) processes in metastatic cas-
cade. Interestingly, the microRNAs identified in our
study are involved in local tumour microenvironmental
changes only. For instance, members of the Let-7 family
are involved in inflammatory processes as a part of the
metastatic cascade. The Let-7 family targets oncogenes such
as HMGA2 and KRAS and seem to be a key component in
a so called epigenetic switch [13-15]. Cancer associated fi-
broblasts are involved in tumor formation and progression
where miR-15 and miR-16 regulate FGF2 and FGFR1 in
prostate cancer [16] and miR-18 in breast cancer [17].
Recently other authors demonstrated that microRNA
371-73 cluster and microRNA 302 discriminated semi-
noma bearing patients from healthy persons [6-8]. We
did the next step and examined the suitability of these
microRNA to predict the metastasis status, these micro-
RNA 371-73 cluster and miRNA 302 was detectable in
our analysis, but appeared not significantly associated
with the metastasis status as it is true for protein tumour
markers (e.g. HCG) as well.
The complete separation of metastasis from non-
metastasized seminoma using a combination of two
small RNA species points to the significant diagnostic
potential of these biological marker which is in line with
previous examinations on the transcriptional level show-
ing the superiority of molecular marker over epidemio-
logical or clinical-histological parameter [18,19]. After
Table 2 Descriptive statistics of number of reads before and after trimming and the percentage of annotated small
RNAs measured in the peripheral blood of patients suffering from seminoma without metastasis as well as lymphogen





Reads after trimming Annotated reads Small RNA tags
abs. % abs. % abs. abs. annotated %
Non-metastasized, n = 5
Mean 1.3E + 07 9.7E + 06 76 8.1E + 06 84 2.2E + 05 1.6E + 04 7.2
Stdev 2.0E + 06 1.6E + 06 2.2 1.4E + 06 2.2 5.4E + 04 3.4E + 03 0.7
Min 9.4E + 06 7.1E + 06 72 5.7E + 06 81 1.7E + 05 1.2E + 04 6.5
Max 1.4E + 07 1.1E + 07 78 9.5E + 06 85 3.1E + 05 2.0E + 04 8.2
Lymphogen metastasized, n = 5
Mean 1.2E + 07 7.8E + 06 73 6.3E + 06 80 2.3E + 05 1.6E + 04 7.3
Stdev 6.5E + 06 3.1E + 06 16 2.7E + 06 3.8 8.6E + 04 3.2E + 03 1.5
Min 5.7E + 06 4.8E + 06 45 3.6E + 06 75 1.5E + 05 1.3E + 04 5.6
Max 2.0E + 07 1.2E + 07 86 1.0E + 07 85 3.3E + 05 1.9E + 04 8.5
Occult metastasized, n = 5
Mean 1.2E + 07 9.0E + 06 73 7.3E + 06 82 2.3E + 05 1.7E + 04 7.8
Stdev 4.3E + 06 3.5E + 06 6.6 2.8E + 06 2.5 5.1E + 04 9.4E + 02 1.4
Min 6.7E + 06 4.7E + 06 64 3.8E + 06 79 1.8E + 05 1.6E + 04 5.9
Max 1.9E + 07 1.4E + 07 81 1.1E + 07 85 3.1E + 05 1.8E + 04 10
Table 1 Characteristics of patients, their biopsies and RNA isolates






pL pV pT Infiltration
rete testis
Initial clinical stage Total RNA (μg) RIN
1 Non metastasized 38 14 0 0 1 n cSI 7.6 7.8
2 50 22 0 0 1 n cSI 8.6 8.3
3 31 19 1 0 1 n cSI 6.4 7.0
4 42 45 0 0 1 y cSI 3.9 8.0
5 35 19 0 0 1 y cSI 8.2 7.6
Mean 39.1 23.8 6.9 7.7
stdev 7.2 12.2 1.9 0.5
1 Lymphogen metastasized 32 40 0 0 1 n cSIIb 5.0 8.5
2 50 12 0 0 3 n cSIIc 5.1 8.8
3 43 50 0 0 1 n cSIIb 8.1 8.3
4 42 45 1 0 2 y cSIIb 3.2 9.3
5 61 42 0 0 1 y cSIIc 3.2 8.2
Mean 45.2 37.8 4.9 8.6
stdev 10.8 14.9 2.0 0.4
1 Occult metastasized 33 55 1 0 2 n cSI 5.0 6.0
2 37 35 0 0 1 y cSI 4.1 7.4
3 37 30 0 0 1 n cSI 7.0 7.8
4 31 18 0 0 1 n cSI 8.1 7.4
5 23 55 0 0 1 n cSI 10.0 6.4
Mean 32.1 38.6 6.8 7.0
stdev 5.4 16.2 2.4 0.8
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Table 3 Summary of significantly associated small RNAs with metastasis status per group using logistic regression analysis (univariate)
Non versus metastasized (lymphogen and occult, n = 35) Non versus lymphogen metastasized (n = 33) Non versus occult metastasized (n = 34)
Small RNA p-value Fold-change 95% confidence interval Small RNA p-value Fold-change 95% confidence
interval
Small RNA p-value Fold-change 95% confidence
interval
let-7f-1 0.04 5.5 1.3 23.7 let-7f-1 0.03 7.2 1.6 32.4 let-7a-1 0.02 3.1 1.4 7.0
mir-16-1 0.05 2.2 1.1 4.5 let-7f-2 0.04 8.1 1.5 44.6 let-7a-2 0.02 3.1 1.4 7.1
mir-18a 0.05 2.4 1.1 5.2 mir-15a 0.05 5.0 1.3 19.4 let-7a-3 0.02 3.1 1.4 7.0
mir-23a 0.05 2.7 1.1 6.5 mir-16-1 0.001 3.2 2.1 5.0 let-7b 0.01 3.1 1.6 6.1
mir-92a-1 0.008 2.7 1.4 5.1 mir-92a-1 0.007 3.0 1.6 5.5 let-7d 0.006 2.7 1.6 4.6
mir-92a-2 0.008 2.8 1.5 5.2 mir-92a-2 0.007 3.0 1.6 5.6 let-7f-1 0.006 3.8 1.9 7.6
mir-99a 0.01 2.5 1.3 4.6 mir-183 0.001 2.5 1.7 3.6 let-7f-2 0.01 3.8 1.7 8.3
mir-183 0.02 2.0 1.2 3.5 let-7 g 0.03 6.2 1.6 23.0 mir-18a 0.04 2.3 1.2 4.5
let-7 g 0.05 4.5 1.2 17.6 mir-15b 0.02 6.8 1.8 26.2 mir-92a-1 0.03 2.5 1.3 4.8
mir-23b 0.04 2.8 1.1 7.1 mir-23b 0.04 3.3 1.3 8.3 mir-92a-2 0.03 2.5 1.3 4.8
mir-130a 0.001 0.2 0.1 0.4 mir-130a 0.04 0.2 0.1 0.7 mir-99a 0.006 2.5 1.5 4.0
mir-191 0.004 0.4 0.2 0.7 mir-142 0.03 0.5 0.3 0.8 let-7 g 0.03 2.9 1.3 6.4
mir-296 0.01 2.3 1.3 4.0 mir-191 0.03 0.4 0.2 0.8 mir-30b 0.03 2.2 1.2 3.8
mir-378a 0.01 2.4 1.3 4.3 mir-126 0.03 2.0 1.2 3.4 mir-130a 0.03 0.1 0.0 0.5
mir-326 0.02 2.7 1.3 5.5 mir-296 0.01 2.2 1.4 3.6 mir-191 0.01 0.4 0.2 0.7
mir-331 0.01 3.0 1.4 6.3 mir-331 0.02 2.7 1.4 5.3 mir-29c 0.04 2.1 1.1 3.8
mir-339 0.04 2.1 1.1 4.0 mir-425 0.05 3.7 1.2 11.0 mir-296 0.04 2.4 1.2 4.7
mir-425 0.01 3.9 1.6 9.4 mir-451a 0.009 2.2 1.4 3.4 mir-378a 0.006 2.5 1.5 4.2
mir-451a 0.002 2.2 1.5 3.2 mir-92b 0.02 2.2 1.3 3.5 mir-326 0.01 3.4 1.7 6.9
mir-92b 0.02 2.5 1.2 5.0 mir-574 0.005 0.3 0.2 0.6 mir-331 0.03 3.3 1.4 7.9
mir-574 0.0001 0.4 0.2 0.5 mir-4286 0.04 3.3 1.3 8.7 mir-339 0.02 2.6 1.4 4.9
mir-4286 0.02 3.9 1.5 10.5 mir-4454 0.008 2.3 1.4 3.7 mir-425 0.002 4.1 2.2 7.5
mir-4454 0.03 2.7 1.2 5.9 ENST00000516594 0.007 0.4 0.2 0.6 mir-451a 0.01 2.2 1.4 3.5
ENST00000516594 0.02 0.5 0.3 0.8 ENST00000363271 0.007 0.4 0.2 0.6 mir-92b 0.04 2.8 1.2 6.4
ENST00000365160 0.03 0.4 0.2 0.8 ENST00000459091 0.002 0.3 0.2 0.5 mir-574 0.0009 0.4 0.3 0.6
ENST00000363271 0.02 0.5 0.3 0.8 ENST00000516350 0.007 0.4 0.2 0.6 mir-660 0.03 2.4 1.3 4.5
ENST00000459091 0.006 0.4 0.3 0.7 ENST00000517209 0.002 0.4 0.2 0.6 mir-664 0.02 2.1 1.3 3.5
ENST00000516350 0.02 0.5 0.3 0.8 ENST00000516507 0.007 0.4 0.2 0.7 mir-4286 0.02 4.5 1.7 11.8
ENST00000363865 0.02 0.5 0.3 0.8 ENST00000363865 0.007 0.4 0.2 0.6 mir-4454 0.05 3.0 1.2 7.5

















Table 3 Summary of significantly associated small RNAs with metastasis status per group using logistic regression analysis (univariate) (Continued)
ENST00000364409 0.02 0.5 0.3 0.8 ENST00000364409 0.007 0.4 0.2 0.6 ENST00000387347 0.01 3.1 1.6 6.0
ENST00000363745 0.02 0.5 0.3 0.8 ENST00000363745 0.007 0.4 0.2 0.6 ENST00000482884 0.05 2.6 1.2 5.6
ENST00000387347 0.03 3.0 1.3 7.3 ENST00000461337 0.007 0.4 0.2 0.6 ENST00000459949 0.002 2.3 1.6 3.4
ENST00000459949 0.003 2.0 1.4 2.9 ENST00000410361 0.02 3.3 1.4 7.8




























Figure 1 Venn diagram showing the total number (bold) and overlapping number of significantly associated small RNAs (from Table 3) to
discriminate different metastasis subtypes (lymphogen, occult and the combination of both subtypes) from non-metastasized seminoma.
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http://www.molecular-cancer.com/content/13/1/47validation of these results on a larger group, these find-
ings could help for therapy decision making in favour of
adjuvant chemotherapy or surveillance based on miRNA
expression changes predicting metastasis spread, even if
metastasis spreads are not visible using a CT scan.
Interesting, the discrimination in our study occurred
irrespective of the metastasis subtype and with the same
microRNAs in up to 79%. This was expected, since we
recently demonstrated lymphogen and occult metasta-
sized seminoma to be indistinguishable on the transcrip-
tional and post-transcriptional level (revised version
submitted).
Noteworthy, these changes were examined in the per-
ipheral blood of seminoma patients taken at the time of
the primary tumour’s diagnosis. It can be hypothesized
that our measurements are linked to seminoma tumour
cells circulating in the peripheral blood.
Our study has certain weaknesses such as the low num-
ber of cases examined (total n = 15). However, the molecu-
lar biological methodology applied provides a deepness,
which under financial considerations does not allow large
scale studies. Hence, this study provides hints towards cer-
tain small RNA species comprising a significant diagnostic
potential for prediction of seminoma metastasis based on
examinations in the peripheral blood, but certainly these
candidate small RNA species have to be examined on a
larger independent group for validation purposes. The val-
idation should also include haematogenous metastasized
seminoma (clinical Stage III), not included in this study,to prove the usability in this tumor stage as well. Further-
more, we did not adjust the p-values for multiple compari-
sons, because of the explorative character of this study
and the low sample size. Based on experiences with previ-
ous work we expect about 10-20% of our candidates being
false positives/negatives [20]. However, this study repre-
sents a screening approach. About 100 most promising
candidate genes will be considered for validation in a fol-
lowing study using another group and another method-
ology (qRT-PCR).
Conclusion
Metastasized (either lymphogen or occult) seminoma
can be completely discriminated from non-metastasized
seminoma with a combination of two small RNAs mea-
sured in the peripheral blood.
Methods
Patient selection
Non-metastasized seminoma (n = 5) received no adjuvant
treatment and were free of relapse/progress for at least
two years of follow up. Occult metastasized patients (n =
5) presented without visible metastasis at primary staging,
received no adjuvant treatment, and developed retroperi-
toneal tumour progress during the follow up of 12 month.
For patients with detectable metastasis at primary staging
(n = 5) we focused on clinical stage IIb and IIc, to include
lymphogenic metastatic spread only and to provide a high
level of diagnostic accuracy (avoiding doubtful lymph
Table 4 Summary on combinations of two small RNAs (small RNA1 with small RNA2) which together completely
discriminate metastasis subtypes (lymphogen, occult and their combination) from non-metastasized seminoma
employing support vector machines
Non versus metastasized
(lymphogen and occult, n = 87)
Non versus lymphogen metastasized
(n = 87 from 891)
Non versus occult metastasized
(=87 from 668)
Small RNA1 Small RNA2 Small RNA1 Small RNA2 Small RNA1 Small RNA2
let-7f-1 mir-191 let-7a-1 mir-192 let-7a-1 mir-223
let-7f-1 mir-574 let-7a-1 mir-191 let-7a-1 mir-574
let-7f-2 mir-191 let-7a-1 mir-532 let-7a-1 mir-4454
mir-18a mir-532 let-7a-1 ENST00000516594 let-7a-2 mir-223
mir-19b-1 mir-342 let-7a-1 ENST00000363271 let-7a-2 mir-574
mir-19b-1 ENST00000517209 let-7a-1 ENST00000459091 let-7a-2 mir-4454
mir-19b-2 mir-342 let-7a-1 ENST00000516350 let-7a-3 mir-223
mir-19b-2 ENST00000517209 let-7a-1 ENST00000517209 let-7a-3 mir-574
mir-28 mir-574 let-7a-1 ENST00000516501 let-7a-3 mir-4454
mir-29a mir-223 let-7a-1 ENST00000516507 let-7b mir-16-1
mir-29a mir-574 let-7a-1 ENST00000363865 let-7b mir-19b-1
mir-93 mir-532 let-7a-1 ENST00000362808 let-7b mir-19b-2
mir-99a mir-574 let-7a-1 ENST00000364409 let-7b mir-22
mir-192 ENST00000459091 let-7a-1 ENST00000363745 let-7b mir-23a
mir-197 mir-92b let-7a-1 ENST00000461337 let-7b mir-24-1
mir-197 mir-4454 let-7a-2 mir-192 let-7b mir-24-2
mir-183 mir-191 let-7a-2 mir-191 let-7b mir-25
mir-223 mir-145 let-7a-2 mir-532 let-7b mir-26a-1
mir-223 mir-423 let-7a-2 ENST00000516594 let-7b mir-26b
mir-223 mir-664 let-7a-2 ENST00000363271 let-7b mir-28
mir-223 ENST00000459091 let-7a-2 ENST00000459091 let-7b mir-29a
mir-30b mir-574 let-7a-2 ENST00000516350 let-7b mir-29b-1
mir-125b-1 mir-130a let-7a-2 ENST00000517209 let-7b mir-29b-2
mir-130a mir-142 let-7a-2 ENST00000516501 let-7b mir-103a-2
mir-130a mir-125b-2 let-7a-2 ENST00000516507 let-7b mir-103a-1
mir-130a mir-150 let-7a-2 ENST00000363865 let-7b mir-107
mir-130a mir-186 let-7a-2 ENST00000362808 let-7b mir-16-2
mir-130a mir-361 let-7a-2 ENST00000364409 let-7b mir-192
mir-130a mir-340 let-7a-2 ENST00000363745 let-7b mir-197
mir-130a mir-342 let-7a-2 ENST00000461337 let-7b mir-181a-2
mir-130a mir-574 let-7a-3 mir-192 let-7b mir-182
mir-140 mir-342 let-7a-3 mir-191 let-7b mir-181a-1
mir-140 mir-532 let-7a-3 mir-532 let-7b mir-221
mir-142 mir-326 let-7a-3 ENST00000516594 let-7b mir-223
mir-142 mir-423 let-7a-3 ENST00000363271 let-7b mir-23b
mir-142 mir-425 let-7a-3 ENST00000459091 let-7b mir-125b-1
mir-142 mir-451a let-7a-3 ENST00000516350 let-7b mir-130a
mir-191 mir-92b let-7a-3 ENST00000517209 let-7b mir-140
mir-29c mir-342 let-7a-3 ENST00000516501 let-7b mir-142
mir-29c mir-574 let-7a-3 ENST00000516507 let-7b mir-191
mir-378a mir-532 let-7a-3 ENST00000363865 let-7b mir-125a
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Table 4 Summary on combinations of two small RNAs (small RNA1 with small RNA2) which together completely
discriminate metastasis subtypes (lymphogen, occult and their combination) from non-metastasized seminoma
employing support vector machines (Continued)
mir-378a mir-574 let-7a-3 ENST00000362808 let-7b mir-125b-2
mir-342 mir-423 let-7a-3 ENST00000364409 let-7b mir-126
mir-342 mir-425 let-7a-3 ENST00000363745 let-7b mir-186
mir-342 mir-3676 let-7a-3 ENST00000461337 let-7b mir-320a
mir-342 ENST00000387347 let-7b mir-192 let-7b mir-106b
mir-342 ENST00000482884 let-7b mir-191 let-7b mir-29c
mir-326 mir-532 let-7b mir-532 let-7b mir-296
mir-326 mir-574 let-7b ENST00000516594 let-7b mir-26a-2
mir-326 ENST00000517209 let-7b ENST00000363271 let-7b mir-361
mir-423 mir-574 let-7b ENST00000459091 let-7b mir-378a
mir-425 mir-532 let-7b ENST00000516350 let-7b mir-340
mir-425 mir-629 let-7b ENST00000517209 let-7b mir-328
mir-425 ENST00000517209 let-7b ENST00000516501 let-7b mir-342
mir-451a mir-574 let-7b ENST00000516507 let-7b mir-326
mir-484 mir-574 let-7b ENST00000363865 let-7b mir-151a
mir-532 mir-92b let-7b ENST00000362808 let-7b mir-331
mir-532 mir-625 let-7b ENST00000364409 let-7b mir-324
mir-532 mir-660 let-7b ENST00000363745 let-7b mir-339
mir-532 ENST00000482884 let-7b ENST00000461337 let-7b mir-345
mir-92b mir-574 let-7d mir-192 let-7b mir-423
mir-574 mir-625 let-7d mir-191 let-7b mir-425
mir-574 mir-454 let-7d mir-532 let-7b mir-451a
mir-574 mir-664 let-7d ENST00000516594 let-7b mir-484
mir-574 mir-4454 let-7d ENST00000363271 let-7b mir-505
mir-574 ENST00000516594 let-7d ENST00000459091 let-7b mir-532
mir-574 ENST00000363271 let-7d ENST00000516350 let-7b mir-574
mir-574 ENST00000459091 let-7d ENST00000517209 let-7b mir-652
mir-574 ENST00000516350 let-7d ENST00000516501 let-7b mir-766
mir-574 ENST00000516507 let-7d ENST00000516507 let-7b mir-744
mir-574 ENST00000363865 let-7d ENST00000363865 let-7b mir-1260a
mir-574 ENST00000362808 let-7d ENST00000362808 let-7b mir-1280
mir-574 ENST00000364409 let-7d ENST00000364409 let-7b mir-1260b
mir-574 ENST00000363745 let-7d ENST00000363745 let-7b mir-4286
mir-574 ENST00000387347 let-7d ENST00000461337 let-7b mir-3676
mir-574 ENST00000459949 let-7f-1 mir-192 let-7b mir-4454
mir-574 ENST00000461337 let-7f-1 mir-191 let-7b ENST00000516572
mir-1260a ENST00000459091 let-7f-1 mir-532 let-7b ENST00000516351
mir-3676 ENST00000517209 let-7f-1 ENST00000516594 let-7b ENST00000516461
mir-4454 ENST00000459091 let-7f-1 ENST00000363271 let-7b ENST00000516775
mir-4454 ENST00000466665 let-7f-1 ENST00000459091 let-7b ENST00000516594
ENST00000516572 ENST00000459091 let-7f-1 ENST00000516350 let-7b ENST00000365160
ENST00000516351 ENST00000459091 let-7f-1 ENST00000517209 let-7b ENST00000363271
ENST00000459091 ENST00000463508 let-7f-1 ENST00000516501 let-7b ENST00000459091
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Table 4 Summary on combinations of two small RNAs (small RNA1 with small RNA2) which together completely
discriminate metastasis subtypes (lymphogen, occult and their combination) from non-metastasized seminoma
employing support vector machines (Continued)
ENST00000459091 ENST00000482884 let-7f-1 ENST00000516507 let-7b ENST00000516350
ENST00000459091 ENST00000488123 let-7f-1 ENST00000363865 let-7b ENST00000517209
ENST00000517209 ENST00000482884 let-7f-1 ENST00000362808 let-7b ENST00000516501
From the total number of small RNA combinations per group (shown in parenthesis) only 87 combinations per group are presented.
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patients were matched with occult metastasized patients
considering demographic and histological parameters
where applicable as well as quality criteria for isolated
RNA (Table 1). All patients included in this study were
treated between 2008 and 2010 in one testis cancer
centre. These 15 patients were selected out of about 300
seminoma patients, according to the criteria mentioned
above.
Histological examination
All testicular tumours (n = 15) were examined by an expe-
rienced pathologist for histological and TNM classification
(Table 1) and pure seminoma was diagnosed in all cases.
Blood sample taking
Whole blood samples (2.5 ml) were taken intraoperative
from cubital vein directly into the PAXgene Blood RNA sys-
tem (BD Diagnostics, PreAnalytiX GmbH, Hombrechtikon,
Switzerland). The tube was gently inverted (10 times),
settled at room temperature overnight and stored at -20°
until use. The Ethical Review Committee of the Medical
Association Hamburg approved the study and all human
samples were obtained with written informed consent.
RNA Isolation
After thawing the PAXGene tubes, and washing and centri-
fugation of the samples the cells became lysed (Proteinase
K) followed by adding Lysis/Binding Solution taken from
the mirVana Kit (Life Technologies, Darmstadt, Germany).
With the mirVana kit total RNA including small RNA spe-
cies was isolated by combining a Phenol-Chloroform RNA
precipitation with further processing using a silica mem-
brane. After several washing procedures DNA residuals
became digested on the membrane (RNAse free DNAse
Set, Qiagen, Hilden, Germany), washed, RNA was eluted
in a collection tube and frozen at -80°C. Quality and quan-
tity of isolated total RNA were measured spectrophoto-
metrically (NanoDrop, PeqLab Biotechnology, Erlangen,
Germany). RNA integrity was assessed by the 2100 Agi-
lent Bioanalyser (Life Science Group, Penzberg, Germany)
and DNA contamination was controlled by conventional
PCR using actin primer.
For analysis, we used only RNA specimens with a ratio of
A260/A280 ≥ 2.0 (Nanodrop) and RNA integrity number(RIN) between 6.0-9.3 for small RNA Next Generation Se-
quencing (IMGM Laboratories, Martinsried, Germany/
CeGat, Tübingen, Germany). For RNA samples with RIN
below 7.0 or questionable 28/18S bands (indications of
RNA degradation) we performed additional checks to ex-
clude the presence of RNAses and true RNA-degradation.Small RNA next generation sequencing and data analysis
We performed a genome wide small RNA sequencing
using the SOLiD5500xl Next Generation Sequencing
Technology (Life Technologies, Penzberg, Germany).
In brief, total RNA was purified (PureLink microRNA
isolation Kit), enriched small RNAs were ligated to
SOLiD adaptors, reverse transcribed (SOLiD RT primer
and ArrayScript RT), cDNA was purified (MinElute
PCR purification Kit, Qiagen), a cut-off size of 60-80 nt
was selected (Novex pre-cast gel products, invitrogen),
cDNA was in-gel amplified and samples were barcoded
using SOLiD 3′Barcode primer at the same time. Amp-
lified cDNA was purified (PureLink PCR Micro Kit,
Life Technologies) and used in emulsion PCR (SOLiD
EZ Bead). Thereafter, the emulsion was broken to re-
cover enriched beads and the so-called di-base probes
were used by the SOLiD system in the sequencing-by-
ligation procedure. Beside the SOLiD5500xl inherent
software (LifeScope) used for image and signal pro-
cessing, software CLC Genomics Workbench 5.1 (CLC
bio) was used for clustering, counting, and annotation
of all generated 75 bp reads. After discarding reads
without adaptor sequence and being shorter than 15 bp
(trimming) reads were assigned to known microRNAs
(Sanger miRBase release 18, http://www.mirbase.org/)
and known non-coding RNAs (ensembl database Homo_
sapiens.GRCh37.67.ncrna.fa, www.ensembl.org). Small
RNAs showing a significant and ≥ 2-fold differences in
gene expression among groups and at least 50 reads
were further analysed on their ability to separate both
groups using univariate logistic regression analysis [21]
and combinations of two small RNAs were examined
employing support vector machines (linear Kermel).
Abbreviations
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